View More Recent Stories

Aug 15, 2022 09:00AM  Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space
Aug 15, 2022 09:00AM Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist
Jul 20, 2022 07:30AM Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs
Jul 15, 2022 07:30AM Awakn Life Sciences Provides a Business and Corporate Update
Jul 5, 2022 07:30AM Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program - Ketamine-Assisted Therapy for Alcohol Use Disorder
Jun 21, 2022 07:00AM CEO Presenting on the Emerging Growth Conference on June 22 Register Now
Jun 17, 2022 09:03AM Awakn Life Sciences to Present in Upcoming June 2022 Conferences
Jun 14, 2022 05:00PM Awakn Life Sciences Reports Results for Quarter Ended April 30, 2022
Jun 7, 2022 07:30AM Awakn Life Sciences Appoints Biotech and Investment Veteran Dennis Purcell as a Special Advisor to the CEO
Jun 2, 2022 07:30AM Awakn Life Sciences Initiates Follow-On Behavioral Study to Focus on Gambling Disorder
May 26, 2022 07:30AM Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application for the Treatment of Behavioral Addictions
May 24, 2022 07:30AM Awakn Life Sciences CEO, Anthony Tennyson, Joins Dustin Robinson of Iter Investments for 'The Investor Hotseat' via Live Stream on May 26th
May 19, 2022 07:56AM Awakn Life Sciences Completes World's First Ketamine Treatment Study for a Range of Behavioral Addictions
May 17, 2022 07:30AM Awakn Life Sciences Appoints UK Leader in Addictions Psychiatry, Dr. Arun Dhandayudham, as Chief Medical Officer
May 5, 2022 07:30AM Awakn Life Sciences to Participate in Upcoming May 2022 Conferences
Apr 28, 2022 04:30PM Awakn Life Sciences Reports Fiscal Fourth Quarter and Fiscal Year January 31, 2022, Results
Apr 13, 2022 07:30AM Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway
Apr 6, 2022 07:30AM Awakn Successfully Completes Phase One of Its Drug Discovery Program
Apr 5, 2022 07:30AM Awakn Life Sciences to Participate in Upcoming April 2022 Conferences
Mar 22, 2022 07:30AM Awakn Life Sciences Announces Closing of Private Placement
Mar 17, 2022 07:30AM Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
Mar 15, 2022 07:30AM Awakn Life Sciences Appoints Kevin Lorenz as U.S. Head of Commercial Development
Mar 9, 2022 07:30AM Awakn Life Sciences to Participate at Upcoming March 2022 Conferences
Feb 17, 2022 07:30AM Awakn Life Sciences Drug Discovery Program Files Patent Application for a New Class of Entactogen-Like Molecules
Feb 15, 2022 07:30AM Awakn Life Sciences' Professor Celia Morgan Named One of the Most Influential Women in the Psychedelics Industry
Feb 10, 2022 07:30AM Awakn Life Sciences to Host Fireside Chat with Dr. Ben Sessa, Chief Medical Officer, on March 2nd at 11:00am EST
Jan 26, 2022 07:30AM Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions
Jan 19, 2022 07:30AM Awakn Life Sciences Signs MOU with Maps
Jan 14, 2022 06:00PM Awakn Responds to OTC Markets Request on Recent Promotional Activity
Jan 11, 2022 07:30AM Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial
Jan 5, 2022 07:30AM Awakn Life Sciences Expands World's First Ketamine Study Beyond Gambling Disorder to Include Additional Behavioral Addictions
Jan 4, 2022 08:28AM Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders
Dec 15, 2021 07:30AM Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights
Dec 14, 2021 07:30AM Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent Member of its Board of Directors
Dec 3, 2021 07:30AM Awakn Life Sciences to Participate at Upcoming December Conferences
Nov 30, 2021 07:30AM Awakn Life Sciences Strengthens Executive Leadership Team
Nov 16, 2021 07:43AM Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK
Nov 4, 2021 07:30AM Awakn Life Sciences Announces the Findings from the Phase II A/B Study Are to Be Published in the American Journal of Psychiatry
Nov 2, 2021 07:30AM Awakn Life Sciences to Participate at the Wonderland: Miami Conference in November 2021
Oct 28, 2021 07:30AM Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery Program
Oct 22, 2021 09:00AM Awakn Life Sciences to Present at the Benzinga Global Small Cap Conference
Oct 20, 2021 07:30AM Awakn Life Sciences Bristol Clinic Receives Care Quality Commission Approval to Begin Treatments in the UK's First Medical Psychedelic Clinic
Oct 8, 2021 04:30PM Awakn Life Sciences to Present at the KCSA Psychedelics Virtual Investor Conference on October 13th
Oct 5, 2021 07:30AM Awakn Life Sciences Announces Closing of Acquisition of Leading Ketamine-Assisted Psychotherapy Clinic in Norway
Sep 23, 2021 07:30AM Awakn Life SciencesAcquires Exclusive Rights to MDMA Research from Imperial College London
Sep 20, 2021 02:00PM Awakn Life Sciences to Present at the Oppenheimer and Maxim Group September Investor Conferences
Sep 16, 2021 07:53AM Awakn Life Sciences to Acquire Leading Ketamine-Assisted Psychotherapy Clinic in Norway
Sep 15, 2021 07:30AM Awakn Life Sciences Reports Second Quarter 2021 Financial Results and Business Highlights
Sep 9, 2021 07:30AM Awakn Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 24, 2021 07:30AM Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan
View More Recent Stories